The largest-ever trial investigating ketamine-assisted therapy for alcohol disorder is now recruiting participants. Led by the University of Exeter, the £2.4 million phase III trial, known as the Multicentre Investigation of Ketamine for Reduction of Alcohol Relapse (MORE-KARE), aims to explore whether this combined treatment could help individuals reduce alcohol consumption. The trial will involve participants at eight NHS sites across the UK, including Oxford Health. It is funded by the National Institute for Health and Care Research (NIHR), the Medical Research Council (MRC), and Awakn Life Sciences. The trial’s objective is to provide an effective treatment alternative for the over half a million UK adults struggling with alcohol problems. Participants will be followed up for up to six months to assess the impact of the intervention on alcohol relapse rates.

Source: Oxford Health NHS